Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124

PURPOSE: Irinotecan plus cisplatin (IP) improved survival over etoposide plus cisplatin (EP) in Japanese patients with extensive-stage small-cell lung cancer (E-SCLC). To confirm those results and discern the potential role of population-related pharmacogenomics (PG) in outcomes, we conducted a larg...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Lara, Primo N., Natale, Ronald, Crowley, John, Lenz, Heinz Josef, Redman, Mary W., Carleton, Jane E., Jett, James, Langer, Corey J., Kuebler, J. Philip, Dakhil, Shaker R., Chansky, Kari, Gandara, David R.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Clinical Oncology 2009
נושאים:
Original Reports
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC2684855/
https://ncbi.nlm.nih.gov/pubmed/19349543
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.1061
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים